Pamapimod/pioglitazone - Curatis
Alternative Names: KIN-001; KIN001-AMD; KIN001-IPF; KINFAST; Pioglitazone/pamapimod - CuratisLatest Information Update: 02 Sep 2024
At a glance
- Originator Kinarus AG
- Developer Curatis
- Class Alcohols; Anti-inflammatories; Antifibrotics; Antihyperglycaemics; Antirheumatics; Antivirals; Eye disorder therapies; Pyridines; Pyridones; Pyrimidines; Small molecules; Thiazolidinediones
- Mechanism of Action P38 mitogen-activated protein kinase inhibitors; Peroxisome proliferator-activated receptor gamma agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II COVID 2019 infections; Wet age-related macular degeneration
- Phase I Idiopathic pulmonary fibrosis
- Preclinical Rheumatoid arthritis; Unspecified
Most Recent Events
- 03 Oct 2023 Kinarus AG suspends a phase II KIN-FAST trial in COVID-2019 infections in Germany and Switzerland (PO), due to financial issues (NCT05659459)
- 12 Apr 2023 Preclinical trials in Unspecified in Switzerland (unspecified route) (Kinarus AG pipeline, April 2023)
- 03 Jan 2023 Chemical structure information added